Study guide
3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS)
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS)
Key Takeaways Explain This Topic AI
Absolute bioavailability (F) represents the fraction of an extravascular dose reaching systemic circulation intact, quantified by comparing dose-normalized AUC against an intravenous reference.
Health Canada bioequivalence standards mandate that the 90% confidence interval for the geometric mean ratio (Test/Reference) of AUC and Cmax must fall within 80.00% to 125.00% for standard drugs.
For Critical Dose Drugs (Narrow Therapeutic Index drugs like warfarin, cyclosporine, digoxin, and lithium), Health Canada enforces a tighter 90% confidence interval requirement of 90.00% to 112.00%.
The Biopharmaceutics Classification System (BCS) categorizes drugs into four classes based on aqueous solubility and intestinal permeability, enabling biowaivers for qualifying Class I and Class III immediate-release solid oral dosage forms.
Food effects, gastrointestinal pH changes, and formulation excipients significantly alter the rate (Cmax, Tmax) and extent (AUC) of drug absorption, especially for BCS Class II and IV molecules.
Last updated: August 2026
3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS)
In pharmacokinetics, the rate and extent to which an active pharmaceutical ingredient is delivered from a dosage form into the systemic circulation dictates its clinical efficacy and safety profile. Biopharmaceutics examines the interrelationship between the physicochemical properties of the drug, the dosage form in which it is presented, and the route of administration.
1. Bioavailability ( F F F ): Definitions and Mathematical Quantification
Bioavailability refers to the rate and extent to which the active moiety is absorbed from a pharmaceutical form and becomes available at the site of physiological action. +-------------------------------------------------------------------------------------+
- | PLASMA CONCENTRATION-TIME PROFILE (ORAL) |
- +-------------------------------------------------------------------------------------+
- | Concentration (C) |
- | ^ |
- | | *** (Cmax, Tmax) |
- | | * * |
- | | * * |
- | | * Absorption * Elimination Phase |
- | | * Phase * |
- | | * * |
- | | * * |
- | | * [AUC(0 to infinity)] * |
- | | * * |
- | | * * |
- | +----------------------------------------*------------> Time (t) |
- | <--- Tmax ---> |
- +-------------------------------------------------------------------------------------+
- Absolute Bioavailability ( F abs F_{\text{abs}} F abs )
Absolute bioavailability compares the systemic exposure of an extravascularly administered drug (e.g., oral, subcutaneous, intramuscular, transdermal) to that of an equivalent intravenous (IV) bolus, where bioavailability is defined as 1.0 1.0 1.0 ( 100 % 100\% 100% ): F abs = AUC oral ⋅ Dose IV AUC IV ⋅ Dose oral = AUC oral / Dose oral AUC IV / Dose IV F_{\text{abs}} = \frac{\text{AUC}_{\text{oral}} \cdot \text{Dose}_{\text{IV}}}{\text{AUC}_{\text{IV}} \cdot \text{Dose}_{\text{oral}}} = \frac{\text{AUC}_{\text{oral}} / \text{Dose}_{\text{oral}}}{\text{AUC}_{\text{IV}} / \text{Dose}_{\text{IV}}} F abs = AUC IV ⋅ Dose oral AUC oral ⋅ Dose IV = AUC IV / Dose IV AUC oral / Dose oral
Physiologically, absolute oral bioavailability is the product of three distinct anatomical fractions: F = f a ⋅ ( 1 − E g ) ⋅ ( 1 − E h ) F = f_a \cdot (1 - E_g) \cdot (1 - E_h) F = f a ⋅ ( 1 − E g ) ⋅ ( 1 − E h )
Where:
f a f_a f a is the fraction of drug absorbed across the apical membrane of the intestinal enterocytes.
E g E_g E g is the gut-wall extraction ratio (gut first-pass metabolism by CYP3A4/5, UGTs, or apical P-gp efflux).
E h E_h E h is the hepatic extraction ratio (first-pass clearance by hepatic enzymes and biliary excretion).
Relative Bioavailability ( F rel F_{\text{rel}} F rel )
Relative bioavailability compares the systemic exposure of two different formulations, salt forms, or non-intravenous routes of administration (e.g., generic tablet formulation T T T versus innovator reference brand R R R , or oral suspension versus tablet): F rel = AUC Test ⋅ Dose Reference AUC Reference ⋅ Dose Test F_{\text{rel}} = \frac{\text{AUC}_{\text{Test}} \cdot \text{Dose}_{\text{Reference}}}{\text{AUC}_{\text{Reference}} \cdot \text{Dose}_{\text{Test}}} F rel = AUC Reference ⋅ Dose Test AUC Test ⋅ Dose Reference
Area Under the Curve (AUC) Calculation
The total extent of systemic drug exposure is calculated using the Linear-Log Trapezoidal Rule from time zero to infinity: AUC 0 − ∞ = AUC 0 − t last + C last k e \text{AUC}_{0-\infty} = \text{AUC}_{0-t_{\text{last}}} + \frac{C_{\text{last}}}{k_e} AUC 0 − ∞ = AUC 0 − t last + k e C last
Where C last C_{\text{last}} C last is the final quantifiable plasma concentration and k e k_e k e is the terminal elimination rate constant.
2. Bioequivalence (BE) and Canadian Regulatory Standards
Two pharmaceutical products are considered bioequivalent if they are pharmaceutical equivalents or pharmaceutical alternatives and their bioavailabilities (rate and extent of absorption) after administration in the same molar dose under similar conditions are sufficiently similar that their effects, with respect to both efficacy and safety, will be essentially the same.
Core Pharmacokinetic Metrics Evaluated in BE Studies
Extent of Absorption : Measured by the Area Under the Concentration-Time Curve from time zero to the last quantifiable concentration ( AUC 0 − t \text{AUC}_{0-t} AUC 0 − t ) and extrapolated to infinity ( AUC 0 − ∞ \text{AUC}_{0-\infty} AUC 0 − ∞ ).
Rate of Absorption : Assessed primarily by the Maximum Plasma Concentration ( C max C_{\text{max}} C max ) and the Time to Maximum Plasma Concentration ( T max T_{\text{max}} T max ). +-------------------------------------------------------------------------------------+
- | HEALTH CANADA BIOEQUIVALENCE COMPARISON (TEST vs. REFERENCE) |
- +-------------------------------------------------------------------------------------+
- | |
- | Standard Drugs: |
- | [================= 80.00% ======= 100.00% ======= 125.00% =================] |
- | ^-- 90% CI for AUC must fall entirely within --^ |
- | ^-- Point estimate for Cmax (80.0-125.0%) -----^ |
- | |
- | Critical Dose Drugs (Narrow Therapeutic Index): |
- | [======= 90.00% ======= 100.00% ======= 112.00% =======] |
- | ^-- 90% CI for BOTH AUC and Cmax within --^ |
- | |
- +-------------------------------------------------------------------------------------+
- Health Canada Specific Bioequivalence Standards
Health Canada's Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies outlines strict statistical criteria:
Standard Drug Formulations :
AUC : The 90 % 90\% 90% confidence interval for the geometric mean ratio (Test / Reference) of AUC 0 − t \text{AUC}_{0-t} AUC 0 − t must fall entirely within the acceptance range of 80.00 % to 125.00 % 80.00\% \text{ to } 125.00\% 80.00% to 125.00% ( 0.8000 − 1.2500 0.8000 - 1.2500 0.8000 − 1.2500 ).
C max C_{\text{max}} C max : The relative mean ( C max C_{\text{max}} C max point estimate) of the Test product to Reference product must be between 80.0 % to 125.0 % 80.0\% \text{ to } 125.0\% 80.0% to 125.0% (for some specific drug categories, the 90 % 90\% 90% confidence interval is required).
Critical Dose Drugs / Narrow Therapeutic Index (NTI) Drugs :
Drugs where small differences in dose or concentration may lead to serious therapeutic failures or life-threatening adverse drug reactions (e.g., cyclosporine, digoxin, flecainide, lithium, phenytoin, tacrolimus, theophylline, warfarin ).
Health Canada enforces a tightened acceptance interval: The 90 % 90\% 90% confidence interval for the geometric mean ratio (Test / Reference) of BOTH AUC 0 − t \text{AUC}_{0-t} AUC 0 − t and C max C_{\text{max}} C max must fall entirely within 90.00 % to 112.00 % 90.00\% \text{ to } 112.00\% 90.00% to 112.00% ( 0.9000 − 1.1200 0.9000 - 1.1200 0.9000 − 1.1200 ).
Study Design Elements :
Standard design is a randomized, single-dose, two-period, two-sequence crossover ( 2 × 2 2 \times 2 2 × 2 ) study conducted in healthy adult human volunteers.
Washout Period : Must be a minimum of 5 elimination half-lives 5 \text{ elimination half-lives} 5 elimination half-lives ( 5 × t 1 / 2 5 \times t_{1/2} 5 × t 1/2 ) of the active drug and any active metabolites to guarantee complete systemic clearance before the crossover sequence.
Fasted vs. Fed Studies : Required under both fasting and high-fat fed conditions for modified-release formulations and immediate-release drugs known to exhibit substantial food effects.
3. The Biopharmaceutics Classification System (BCS)
The BCS is a scientific framework developed by Amidon et al. and standardized by Health Canada and the International Council for Harmonisation (ICH M9 Guideline). It classifies active pharmaceutical ingredients based on their aqueous solubility and intestinal permeability. +-------------------------------------------------------------------------------------+
- | BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) |
- +-------------------------------------------------------------------------------------+
- | AQUEOUS SOLUBILITY |
- | HIGH LOW |
- | +-----------------------------------+-----------------------------------+ |
- | H | CLASS I | CLASS II | |
- | I | High Solubility, High Permeability| Low Solubility, High Permeability | |
- | G | - Rapid dissolution & absorption | - Dissolution-rate limited | |
- | H | - Candidate for Biowaiver | - High food effect (lipids help) | |
- | P | - E.g., Metoprolol, Acetaminophen | - E.g., Ibuprofen, Carbamazepine | |
- | E +-----------------------------------+-----------------------------------+ |
- | R L | CLASS III | CLASS IV | |
- | M O | High Solubility, Low Permeability | Low Solubility, Low Permeability | |
- | W | - Permeability-rate limited | - Formulation & absorption poorly | |
- | | - Strict Biowaiver criteria | predictable; low bioavailability| |
- | | - E.g., Atenolol, Cimetidine | - E.g., Furosemide, Paclitaxel | |
- | +-----------------------------------+-----------------------------------+ |
- +-------------------------------------------------------------------------------------+
- Regulatory Definitions of Solubility and Permeability
High Solubility (Health Canada / ICH M9) : The highest single therapeutic dose of an immediate-release dosage form dissolves completely in ≤ 250 mL \le 250\text{ mL} ≤ 250 mL of aqueous media across the entire physiological pH range of pH 1.2 to 6.8 \text{pH } 1.2 \text{ to } 6.8 pH 1.2 to 6.8 at 37 ± 1 ∘ C 37 \pm 1^\circ\text{C} 37 ± 1 ∘ C .
High Permeability : An extent of systemic absorption in humans ≥ 85 % \ge 85\% ≥ 85% of an administered dose based on mass balance determinations or in comparison to an intravenous reference dose.
Detailed Breakdown of BCS Classes
BCS Class Solubility Permeability Rate-Limiting Step in Absorption Formulation Challenges & Strategies Representative Drug Examples
Class I High High Gastric emptying rate None; rapid dissolution ensures complete systemic uptake. Acetaminophen, metoprolol, propranolol, diltiazem, zidovudine
Class II Low High Drug dissolution rate ( i n v i v o in\ vivo in v i v o ) Must enhance surface area or solubility: micronization, solid dispersions, cyclodextrin complexes, lipid-based self-emulsifying drug delivery systems (SEDDS). Ibuprofen, ketoconazole, carbamazepine, atorvastatin, cyclosporine, itraconazole
Class III High Low Intestinal membrane permeation rate Formulation excipients must not alter transit time or transporter activity; permeation enhancers required. Atenolol, metformin, cimetidine, acyclovir, enalaprilat
Class IV Low Low Both dissolution and membrane permeation Extreme formulation hurdles; poor oral bioavailability; parenteral or novel nanocarriers often required. Furosemide, hydrochlorothiazide, paclitaxel, ritonavir
4. BCS-Based Biowaivers and In Vitro Dissolution Standards
A biowaiver permits the approval of an in vivo bioequivalence study exemption for an immediate-release solid oral generic formulation based on surrogate in vitro dissolution testing.
Regulatory Criteria for Biowaivers (ICH M9 / Health Canada)
BCS Class I Substances :
Active pharmaceutical ingredient meets high solubility and high permeability criteria.
Very Rapid Dissolution : ≥ 85 % \ge 85\% ≥ 85% of the labeled active drug dissolves within 15 minutes 15\text{ minutes} 15 minutes , or
Rapid Dissolution : ≥ 85 % \ge 85\% ≥ 85% of the labeled active drug dissolves within 30 minutes 30\text{ minutes} 30 minutes using USP Apparatus I (basket at 100 rpm 100\text{ rpm} 100 rpm ) or Apparatus II (paddle at 50 rpm 50\text{ rpm} 50 rpm ) across three distinct buffer media:
- pH 1.2 (0.1 N HCl or simulated gastric fluid without enzymes)
- pH 4.5 (acetate buffer)
- pH 6.8 (phosphate buffer or simulated intestinal fluid without enzymes)
Excipients must be standard, conventional, and qualitatively/quantitatively similar to the reference.
BCS Class III Substances :
High solubility and low permeability.
Must exhibit very rapid dissolution ( ≥ 85 % \ge 85\% ≥ 85% in 15 minutes 15\text{ minutes} 15 minutes ) across all three physiological buffers.
Strict Excipient Restrictions : Generic and reference products must be qualitatively identical and quantitatively very similar in excipient composition, as excipients can drastically alter intestinal transit time or membrane transporters.
Ineligible Drugs : Biowaivers are never granted for Critical Dose Drugs (Narrow Therapeutic Index drugs) or orally disintegrating / sublingual tablets intended for buccal absorption.
5. Food Effects and Excipient Interactions
Co-administration of drugs with food can drastically alter oral bioavailability through physiological and physicochemical mechanisms. +-------------------------------------------------------------------------------------+
- | MECHANISMS OF FOOD-DRUG INTERACTIONS |
- +-------------------------------------------------------------------------------------+
- | Physiological Changes: |
- | - Delayed Gastric Emptying : Increases Tmax; delays onset of action |
- | - Splanchnic Blood Flow Surge : Decreases first-pass extraction (propranolol) |
- | - Bile Salt Secretion : Enhances micellar solubilization of Class II drugs |
- | - Gastric Acid Secretion : Lowers pH (enhances ketoconazole/atazanavir) |
- | |
- | Physicochemical Interactions: |
- | - Polyvalent Cation Chelation : Ca2+, Mg2+, Fe2+, Al3+ bind tetracyclines/quinolones|
- | - Meal Viscosity & Binding : Dietary fibers bind digoxin and levothyroxine |
- +-------------------------------------------------------------------------------------+
Bile Micellar Solubilization : High-fat meals stimulate cholecystokinin release, triggering gallbladder contraction. Bile acids (taurocholic acid) and lecithin form mixed micelles that solubilize poorly water-soluble lipophilic drugs (BCS Class II, such as isotretinoin, griseofulvin, ziprasidone, vemurafenib ), markedly increasing their oral bioavailability.
Chelation Interactions : Polyvalent cations ( Ca 2 + \text{Ca}^{2+} Ca 2 + , Mg 2 + \text{Mg}^{2+} Mg 2 + , Al 3 + \text{Al}^{3+} Al 3 + , Fe 2 + \text{Fe}^{2+} Fe 2 + , Zn 2 + \text{Zn}^{2+} Zn 2 + ) in dairy products, antacids, or mineral supplements form insoluble, non-absorbable coordination complexes with fluoroquinolones (ciprofloxacin, levofloxacin), tetracyclines (doxycycline, minocycline), and bisphosphonates (alendronate, risedronate), reducing systemic exposure by up to 80 − 99 % 80-99\% 80 − 99% .
Empty-Stomach Mandates : Bisphosphonates must be taken after an overnight fast with a full glass of plain water, remaining upright and fasting for ≥ 30 − 60 minutes \ge 30-60\text{ minutes} ≥ 30 − 60 minutes to avoid complete loss of systemic absorption and chemical esophagitis.